EDITORIAL
Published on 30 Nov 2022
Editorial: Drugging p53 for non-cancer diseases
doi 10.3389/fphar.2022.1101742
- 795 views
- Frontiers in Pharmacology
- Experimental Pharmacology and Drug Discovery
- Research Topics
- Drugging p53 for Non-Cancer Diseases
Drugging p53 for Non-Cancer Diseases
6,430
Total downloads
17k
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Articles
ORIGINAL RESEARCH
Published on 26 Oct 2022
A transcriptional program associated with cell cycle regulation predominates in the anti-inflammatory effects of CX-5461 in macrophage
doi 10.3389/fphar.2022.926317
- 1,536 views
- 3 citations
ORIGINAL RESEARCH
Published on 20 Sep 2022
AZD6738 Inhibits fibrotic response of conjunctival fibroblasts by regulating checkpoint kinase 1/P53 and PI3K/AKT pathways
doi 10.3389/fphar.2022.990401
- 1,587 views
- 7 citations
REVIEW
Published on 06 Sep 2022
The role of p53 in the alternation of vascular functions
doi 10.3389/fphar.2022.981152
- 3,485 views
- 18 citations
ORIGINAL RESEARCH
Published on 10 Jan 2022
Baicalein Alleviates Osteoarthritis Progression in Mice by Protecting Subchondral Bone and Suppressing Chondrocyte Apoptosis Based on Network Pharmacology
doi 10.3389/fphar.2021.788392
- 3,226 views
- 17 citations
ORIGINAL RESEARCH
Published on 28 Apr 2021
Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators
doi 10.3389/fphar.2021.653233
- 2,125 views
- 12 citations
Published in
Frontiers in Pharmacology
- Experimental Pharmacology and Drug Discovery
Impact
- 17kTopic views
- 10kArticle views
- 6,430Article downloads